Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 7588-36-5 | MDL No. : | MFCD00218549 |
Formula : | C13H15NO3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | JYUNCKSXPPDNRM-UHFFFAOYSA-N |
M.W : | 233.26 | Pubchem ID : | 82067 |
Synonyms : |
|
Num. heavy atoms : | 17 |
Num. arom. heavy atoms : | 9 |
Fraction Csp3 : | 0.31 |
Num. rotatable bonds : | 4 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 65.62 |
TPSA : | 51.32 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.15 cm/s |
Log Po/w (iLOGP) : | 2.39 |
Log Po/w (XLOGP3) : | 2.21 |
Log Po/w (WLOGP) : | 2.2 |
Log Po/w (MLOGP) : | 1.37 |
Log Po/w (SILICOS-IT) : | 3.23 |
Consensus Log Po/w : | 2.28 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.81 |
Solubility : | 0.364 mg/ml ; 0.00156 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.92 |
Solubility : | 0.279 mg/ml ; 0.0012 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.29 |
Solubility : | 0.012 mg/ml ; 0.0000516 mol/l |
Class : | Moderately soluble |
PAINS : | 1.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.03 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280 | UN#: | N/A |
Hazard Statements: | H302-H317 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
100% | Stage #1: With bis-(2-oxo-3-oxazolidinyl)phosphoryl chloride; triethylamine In dichloromethane at 20℃; for 0.0833333 h; Stage #2: at 20℃; |
General procedure: A reaction mixture containing the indoleacetic acid derivative (1 equivalent) and BOP-Cl (1 equivalent) in 3 mL/mmol of anhydrous CH2Cl2 is treated with triethylamine (2 equivalents) and aged at ambient temperature for 5 min. The mixture is combined with anhydrous methanol (0.14 mL/mmol) and then continuously stirred overnight at room temperature. Following dilution with dichloromethane (12 mL/mmol), the organic solution is washed with water (2x6 mL/mmol), dried over Na2SO4, and filtered. The organic filtrate is collected and concentrated in vacuo and the crude ester is purified by flash chromatography on silica gel (ethyl acetate/hexane gradient) to afford the title compound at first as viscous yellow oil, which stably crystallizes upon seeding and subsequent cold storage. |
83% | at 20℃; | General procedure: Indomethacin (3.00 g, 8.39 mmol) was dissolved in 1 M NaOH(200 mL) and left to stir overnight. The reaction was acidified with1 M HCl and the precipitate filtered off. Filtrate was then extractedthree times with DCM (100 mL). Combined organic layer was driedover Na2SO4 and concentrated in vacuo to give crude 2-(5-methoxy-2-methyl-1H-indol-3-yl)acetic acid (1.12 g, 5.15 mmol). Thecrude intermediate was dissolved in MeOH (50 mL) and TMSCl(1.86 mL, 14.73 mmol) was added. The reaction mixture was leftto stir at room temperature overnight. Water (50 mL) was addedto quench the reaction and extracted three times with DCM(50 mL). Organic layer was combined, dried over Na2SO4 and concentratedin vacuo. Residue obtained was purified by column chromatographyusing CHCl3:EtOAc (10:1) to give 12 as a brown solid(0.99 g, 83percent). 1H NMR (400 MHz, CDCl3) d 7.92 (s, 1H), 7.07 (d,J = 8.7 Hz, 1H), 7.01 (d, J = 2.0 Hz, 1H), 6.81–6.75 (m, 1H), 3.87 (d,J = 1.1 Hz, 3H), 3.68 (d, J = 1.0 Hz, 5H), 2.32 (s, 3H). 13C NMR(101 MHz, CDCl3) d 172.8, 154.1, 133.7, 130.2, 129.0, 111.1,110.8, 104.1, 100.4, 55.9, 51.9, 30.3, 11.7. |
[ 2882-15-7 ]
5-Methoxy-2-methyl-3-indoleacetic acid
Similarity: 0.95
[ 3471-31-6 ]
2-(5-Methoxy-1H-indol-3-yl)acetic acid
Similarity: 0.94
[ 172595-68-5 ]
Methyl 5-methoxy-1H-indole-3-carboxylate
Similarity: 0.91
[ 39547-16-5 ]
3-(5-Methoxy-1H-indol-3-yl)propanoic acid
Similarity: 0.91
[ 10242-01-0 ]
5-Methoxy-1H-indole-3-carboxylic acid
Similarity: 0.88
[ 172595-68-5 ]
Methyl 5-methoxy-1H-indole-3-carboxylate
Similarity: 0.91
[ 112332-97-5 ]
Methyl 6-hydroxy-1H-indole-3-carboxylate
Similarity: 0.87
[ 15574-49-9 ]
Ethyl 5-hydroxy-1,2-dimethyl-1H-indole-3-carboxylate
Similarity: 0.84
[ 1912-33-0 ]
Methyl 2-(1H-indol-3-yl)acetate
Similarity: 0.83
[ 77140-48-8 ]
Methyl 4-hydroxy-1H-indole-6-carboxylate
Similarity: 0.83
[ 2882-15-7 ]
5-Methoxy-2-methyl-3-indoleacetic acid
Similarity: 0.95
[ 3471-31-6 ]
2-(5-Methoxy-1H-indol-3-yl)acetic acid
Similarity: 0.94
[ 172595-68-5 ]
Methyl 5-methoxy-1H-indole-3-carboxylate
Similarity: 0.91
[ 39547-16-5 ]
3-(5-Methoxy-1H-indol-3-yl)propanoic acid
Similarity: 0.91
[ 54-16-0 ]
2-(5-Hydroxy-1H-indol-3-yl)acetic acid
Similarity: 0.89